Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension: cLinical and haemodYnamic long-term efficacy (ITALY study)

DOI: 10.2459/jcm.0000000000000590
Journal of Cardiovascular Medicine, 2018, 19, 12-17.

#	Paper	IF	Citations
15	Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?. *Vascular Health and Risk Management*, **2018**, 14, 253-264	4.4	20
14	Ambrisentan tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU. *Drugs and Therapy Perspectives*, **2018**, 34, 289-299	1.5	
13	Effect of Combination Therapy of Endothelin Receptor Antagonist and Phosphodiesterase-5 Inhibitor on Clinical Outcome and Pulmonary Haemodynamics in Patients with Pulmonary Arterial Hypertension: A Meta-Analysis. *Clinical Drug Investigation*, **2019**, 39, 1031-1044	3.2	4
12	Clinical and hemodynamic benefit of macitentan and riociguat upfront combination in patients with pulmonary arterial hypertension. *Pulmonary Circulation*, **2019**, 9, 2045894019826944	2.7	8
11	The importance of right ventricular evaluation in risk assessment and therapeutic strategies: Raising the bar in pulmonary arterial hypertension. *International Journal of Cardiology*, **2020**, 301, 183-189	3.2	22
10	Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan-tadalafil in pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2020**, 39, 1389-1397	5.8	3
9	Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. *European Respiratory Journal*, **2020**, 56,	13.6	12
8	Right-Heart Reverse Remodeling During Treatment for Pulmonary Hypertension. **2021**, 291-299		
7	The Growing Role of Echocardiography in Pulmonary Arterial Hypertension Risk Stratification: The Missing Piece. *Journal of Clinical Medicine*, **2021**, 10,	5.1	6
6	Recent advances in the management of pulmonary arterial hypertension: lessons from the upfront combination of ambrisentan and tadalafil. *Expert Review of Respiratory Medicine*, **2021**, 15, 493-504	3.8	2
5	Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study) - Protocol of a Multicenter Randomized Control Trial. *Circulation Reports*, **2021**, 3, 105-109	0.7	0
4	In vivo Pharmacokinetics and in vitro Release of Imatinib Mesylate-Loaded Liposomes for Pulmonary Delivery. *International Journal of Nanomedicine*, **2021**, 16, 1221-1229	7.3	3
3	Advances in the management of pulmonary arterial hypertension. *Journal of Investigative Medicine*, **2021**, 69, 1270-1280	2.9	4
2	Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis. *Drug Delivery*, **2021**, 28, 1007-1019	7	2
1	Aggressive Afterload Lowering to Improve the RV: A New Target for Medical Therapy in PAH?. *American Journal of Respiratory and Critical Care Medicine*, **2021**,	10.2	2